RIVANOVA
Newsroom
Approvals, expansions, partnerships and recognitions — documented as they happen.
Announcements
Regulatory approvals, capacity expansions, partnerships and recognitions. Media enquiries to admin@rivanovahealthcare.com.
Marketing authorisations have been granted for two anti-infective tablet formulations and one paediatric suspension, taking live product registrations past 180 across 25+ markets. All three were submitted in CTD format and cleared without a second review cycle.
The new suite adds 1.7 lakh tablets per hour and dedicated handling for moisture-sensitive formulations, with an independent air handling unit maintaining below 40% RH. Process validation on three consecutive batches completed prior to commercial release.
Free diabetes, hypertension, anaemia and vision screening was conducted across 42 villages in three districts. Patients diagnosed received three months of medication at no cost along with a referral to their nearest government health facility.
All four production blocks were inspected across five days. Certification was renewed with no critical or major observations recorded. Minor observations were closed within the committed timeframe and verified at follow-up.
A territory-exclusive agreement covering an initial portfolio of 34 SKUs across anti-infectives, analgesics and paediatric formulations. Registration dossiers have been submitted in all four markets, with first consignments expected in the fourth quarter.
The 21 CFR Part 11 compliant electronic batch record system now covers all four production blocks. Audit trails are reviewed by quality assurance prior to batch release, replacing the previous retrospective review process entirely.
The third phase of the rooftop installation has been commissioned, raising renewable generation to 42% of annual consumption. The site remains on a plan to reach 60% by 2028 alongside continued operation of the zero-liquid-discharge effluent plant.
Full-tuition scholarships covering fees, books, laboratory costs and hostel expenses have been awarded to eighteen B.Pharm and D.Pharm students selected on merit and financial need. Recipients carry no obligation to join the company.
Four new protein and amino-acid formulations developed for renal patients have completed stability testing and entered commercial manufacture, blended in dehumidified suites held below 35% relative humidity.
For interview requests, company statements, high-resolution assets or factual verification, contact our communications desk. We respond to media enquiries within one working day.